Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Feasibility of Adjusting Risk Group and Risk Group-Based Therapy during Induction in the Treatment of B-Cell Acute Lymphoblastic Leukemia: Results from DFCI ALL Consortium Protocol 16-001

Lynda M. Vrooman, Yael Flamand, Melissa A. Burns, Victoria B. Koch, Sarah M. Cronholm, Sarah K. Hunt, Peter D. Cole, Lisa M. Gennarini, Marian H. Harris, Nobuko Hijiya, Justine M. Kahn, Kara M. Kelly, Bruno Michon, Andrew E. Place, Thai Hoa Tran, Jennifer J.G. Welch, Stephen E. Sallan, Lewis B. Silverman

Blood (2024) 144 (Supplement 1): 311.

https://doi.org/10.1182/blood-2024-208605

Published: 2024

Journal Articles

Household Material Hardship and Inpatient Days in Dana-Farber Cancer Institute (DFCI) Acute Lymphoblastic Leukemia (ALL) Consortium Trial 16-001

Blood (2024) 144 (Supplement 1): 3649.

https://doi.org/10.1182/blood-2024-199274

Published: 2024

Journal Articles

Efficacy and Toxicity of Fixed Dose Versus Reduced/PK-Adjusted Dose Pegaspargase in Pediatric Patients with Newly Diagnosed Acute Lymphoblastic Leukemia: Results of DFCI ALL Consortium Protocol 16-001

Melissa A. Burns, Yael Flamand, Lynda M. Vrooman, Victoria B. Koch, Yves Theoret, Sarah M. Cronholm, Sarah K. Hunt, Peter D. Cole, Lisa M. Gennarini, Nobuko Hijiya, Justine M. Kahn, Kara M. Kelly, Bruno Michon, Donna S. Neuberg, Andrew E. Place, Thai Hoa Tran, Jennifer J.G. Welch, Stephen E. Sallan, Lewis B. Silverman

Blood (2024) 144 (Supplement 1): 307.

https://doi.org/10.1182/blood-2024-207273

Published: 2024

Journal Articles

Public Insurance As a Proxy Measure of Household Poverty-Exposures Among Children with Hematologic Malignancies

Rahela Aziz-Bose, Morgan A. Paul, Yael Flamand, Colleen A. Kelly, Leanne Duhaney, Puja J. Umaretiya, Lucille Lokko, McKenzie Griffin, Alexandria Hawkins, Peter D. Cole, Lisa M. Gennarini, Justine M. Kahn, Kara M. Kelly, Victoria B. Koch, Bruno Michon, Thai Hoa Tran, Jennifer J.G. Welch, Lewis B. Silverman, Kira Bona

Blood (2024) 144 (Supplement 1): 3750.

https://doi.org/10.1182/blood-2024-205672

Published: 2024

Journal Articles

Anti-Leukemic Activity of Luveltamab Tazevibulin (LT, STRO-002), a Novel Folate Receptor-α (FR-α)-Targeting Antibody Drug Conjugate (ADC) in Relapsed/Refractory CBF2AT3::GLIS2 AML

Blood (2023) 142 (Supplement 1): 4295.

https://doi.org/10.1182/blood-2023-180141

Published: 2023

Journal Articles

Oral Chemotherapy Adherence in Pediatric Acute Lymphoblastic Leukemia (ALL): A Report from the Dana-Farber Cancer Institute (DFCI) ALL Consortium Protocol 16-001

Justine M. Kahn, Hital Patel, Julia Keating, Yael Flamand, Victoria Koch, Peter D. Cole, Lisa M. Gennarini, Bruno Michon, Thai Hoa Tran, Jennifer J.G. Welch, Lewis B. Silverman, Elizabeth Bouchard, Kira Bona, Kara M. Kelly

Blood (2023) 142 (Supplement 1): 7375.

https://doi.org/10.1182/blood-2023-189447

Published: 2023

Journal Articles

Performance of Next Generation Sequencing for Minimal Residual Disease Detection for Pediatric Patients with Acute Lymphoblastic Leukemia: Results from the Prospective Clinical Trial DFCI 16-001

Jonathan D. Paolino, Marian H. Harris, Kristen E. Stevenson, Victoria Koch, Peter D. Cole, Lisa M. Gennarini, Justine M. Kahn, Kara M. Kelly, IIan Kirsch, Bruno Michon, Andrew E. Place, Thai Hoa Tran, Jennifer J.G. Welch, Lewis B. Silverman

Blood (2021) 138 (Supplement 1): 3485.

https://doi.org/10.1182/blood-2021-152369

Published: 2021

Journal Articles

Impact of Age, Body Surface Area, and Body Mass Index on Pegaspargase Toxicity and Pharmacokinetics: A Report from the DFCI ALL Consortium

Blood (2021) 138 (Supplement 1): 3396.

https://doi.org/10.1182/blood-2021-151313

Published: 2021

Journal Articles

Frequency and Prognostic Significance of Recurrent Gene Mutations in Pediatric B-ALL: Report from the DFCI ALL Consortium

Blood (2020) 136 (Supplement 1): 15–16.

https://doi.org/10.1182/blood-2020-136190

Published: 2020

Journal Articles

Pegaspargase Re-Challenge after Grade 2 Hypersensitivity Reaction in Childhood Acute Lymphoblastic Leukemia: Results from DFCI 16-001

Lynda M. Vrooman, MD, Yael Flamand, MS, Victoria Koch, BS, Melissa A. Burns, MD, Sarah M. Cronholm, BA, Sarah K. Hunt, BS, MPH, Peter D. Cole, MD, Lisa M. Gennarini, MD, Justine M. Kahn, MDMSc, Kara M. Kelly, MD, Bruno Michon, MD FRCPC, Donna S. Neuberg, ScD, Andrew E. Place, MDPhD, Thai Hoa Tran, MD, Jennifer J.G. Welch, MD, Kristen E. Stevenson, MS, Stephen E. Sallan, MD, Lewis B. Silverman, MD

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-138840

Published: 2020

Journal Articles

Genetic Ancestry and Skeletal Toxicities Among Childhood Acute Lymphoblastic Leukemia Patients in the DFCI 05-001 Cohort

Qianqian Zhu, PhD, Song Yao, PhD, Peter D Cole, MD, Justine M. Kahn, MD MS, Marian H. Harris, MD PhD, Emily Schiller, MS, Uma Athale, MDMBBS,MSc, Luis A. Clavell, MD, Caroline Laverdiere, MD FRCPC, Jean-Marie Leclerc, MDFRCPC, Bruno Michon, MD FRCPC, Marshall A. Schorin, MD, Jennifer J.G. Welch, MD, Stephen E. Sallan, MD, Lewis B. Silverman, MD, Kara M. Kelly, MD

Blood (2019) 134 (Supplement_1): 3811.

https://doi.org/10.1182/blood-2019-126814

Published: 2019

Journal Articles

Age and ABO Blood Group Are Significant Predictors of Thrombosis in Children with Acute Lymphoblastic Leukemia (ALL): Results from Dana-Farber Cancer Institute (DFCI) ALL Consortium Trial 05-001

Uma H. Athale, MD, M.Sc., Traci M. Blonquist, MS, Kristen E. Stevenson, MS, Menachem Spira, Peter D. Cole, MD, Barbara L Asselin, MD, Luis A. Clavell, MD, Kara M. Kelly, MD, Caroline Laverdière, MDFRCPC, Jean-Marie Leclerc, MD, Bruno Michon, MD, Marshall A. Schorin, MD, Maria Luisa Sulis, MD, Jennifer J.G. Welch, MD, Marian H. Harris, MD PhD, Donna S. Neuberg, ScD, Stephen E. Sallan, MD, Lewis B. Silverman, MD

Blood (2017) 130 (Supplement 1): 1278.

https://doi.org/10.1182/blood.V130.Suppl_1.1278.1278

Published: 2017

Journal Articles

Dietary Antioxidant Micronutrient Intake and Toxicity during Remission Induction in Children with Acute Lymphoblastic Leukemia (ALL): Results from Dana-Farber Cancer Institute (DFCI) ALL Consortium Trial 05-001

Kara M. Kelly, MD, Elena Ladas, PhD, Traci M. Blonquist, MS, Kristen E. Stevenson, MS, Meiko Lin, MA, Peter D Cole, MD, Manuela Orjuela, MD ScM, Uma Athale, Luis A. Clavell, MD, Caroline Laverdière, MDFRCPC, Jean-Marie Leclerc, MDFRCPC, Bruno Michon, MD FRCPC, Marshall A. Schorin, MD, Maria Luisa Sulis, MD, Jennifer J.G. Welch, MD, Barbara L Asselin, MD, Stephen E. Sallan, MD, Lewis B. Silverman, MD

Blood (2017) 130 (Supplement 1): 2549.

https://doi.org/10.1182/blood.V130.Suppl_1.2549.2549

Published: 2017

Journal Articles

Randomized Study of Pegasparagase (SS-PEG) and Calaspargase Pegol (SC-PEG) in Pediatric Patients with Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma: Results of DFCI ALL Consortium Protocol 11-001

Blood (2016) 128 (22): 175.

https://doi.org/10.1182/blood.V128.22.175.175

Published: 2016

Journal Articles

Kinase-Activating Fusions in Pediatric High-Risk B-Lineage Acute Lymphoblastic Leukemia (ALL): a Report from the Dana-Farber Cancer Institute (DFCI) ALL Consortium

Blood (2016) 128 (22): 1729.

https://doi.org/10.1182/blood.V128.22.1729.1729

Published: 2016

Journal Articles

Excellent Outcome of Children with Down Syndrome (DS) and Acute Lymphoblastic Leukemia (ALL) Treated on Dana-Farber Cancer Institute (DFCI) ALL Consortium Protocols 00-001 and 05-001

Uma H. Athale, MD, M.Sc., Maneka Puligandla, MS, Kristen E. Stevenson, MS, Barbara L. Asselin, MD, Luis A. Clavell, MD, Peter D. Cole, MD, Kara M. Kelly, MD, Caroline Laverdiere, MD, Jean-Marie Leclerc, MD, Bruno Michon, MD, Marshall A. Schorin, MD, Maria Luisa Sulis, MD, Jennifer J.G. Welch, MD, Marian H. Harris, MD PhD, Donna S. Neuberg, Sc.D., Stephen E. Sallan, MD, Lewis B. Silverman, MD

Blood (2016) 128 (22): 761.

https://doi.org/10.1182/blood.V128.22.761.761

Published: 2016

Journal Articles

Higher Incidence of Treatment-Related Toxicities in Non-Hispanic Patients Undergoing Therapy for Newly Diagnosed Pediatric Acute Lymphoblastic Leukemia on Dana-Farber Cancer Institute ALL Consortium Protocol 05-001

Justine Kahn, MD, Sergio Barrera, Randy Davila, Emily Roberts, ZheZhen Jin, PhD, Kristen Stevenson, MS, Traci M. Blonquist, MS, Donna S Neuberg, ScD, Uma H. Athale, MD, M.Sc., Luis A. Clavell, MD, Peter Cole, MD, Caroline Laverdiere, MD, Bruno Michon, MD FRCPC, Marshall A. Schorin, MD, Jennifer J.G. Welch, MD, Stephen E. Sallan, MD, Lewis B. Silverman, MD, Kara M. Kelly, MD

Blood (2015) 126 (23): 248.

https://doi.org/10.1182/blood.V126.23.248.248

Published: 2015

Journal Articles

Effectiveness of Antibacterial Prophylaxis during Induction Chemotherapy in Children with Acute Lymphoblastic Leukemia

Maria Luisa Sulis, MD, Traci M. Blonquist, MS, Uma H. Athale, MD, M.Sc., Luis A. Clavell, MD, Peter D. Cole, MD, Kara M. Kelly, MD, Caroline Laverdiere, MD, Jean-Marie Leclerc, MD, Bruno Michon, MD FRCPC, Marshall A. Schorin, MD, Jennifer J.G. Welch, MD, Donna S Neuberg, ScD, Stephen E. Sallan, MD, Lewis B. Silverman, MD

Blood (2015) 126 (23): 249.

https://doi.org/10.1182/blood.V126.23.249.249

Published: 2015

Journal Articles

Ikaros Gene Deletion Significantly Predicts Relapse in Pediatric B-ALL Patients with Low End-Induction Minimal Residual Disease

Marian H. Harris, MD PhD, Traci M. Blonquist, MS, Uma H. Athale, MD, M.Sc., Luis A. Clavell, MD, Peter D. Cole, MD, Kara M. Kelly, MD, Caroline Laverdiere, MD, Jean-Marie Leclerc, MD, Bruno Michon, MD FRCPC, Marshall A. Schorin, MD, Jennifer J.G. Welch, MD, Donna S. Neuberg, Sc.D., Stephen E. Sallan, MD, Lewis B. Silverman, MD

Blood (2015) 126 (23): 2613.

https://doi.org/10.1182/blood.V126.23.2613.2613

Published: 2015

NARROW

Feasibility of Adjusting Risk Group and Risk Group-Based Therapy during Induction in the Treatment of B-Cell Acute Lymphoblastic Leukemia: Results from DFCI ALL Consortium Protocol 16-001

Household Material Hardship and Inpatient Days in Dana-Farber Cancer Institute (DFCI) Acute Lymphoblastic Leukemia (ALL) Consortium Trial 16-001

Efficacy and Toxicity of Fixed Dose Versus Reduced/PK-Adjusted Dose Pegaspargase in Pediatric Patients with Newly Diagnosed Acute Lymphoblastic Leukemia: Results of DFCI ALL Consortium Protocol 16-001

Public Insurance As a Proxy Measure of Household Poverty-Exposures Among Children with Hematologic Malignancies

Anti-Leukemic Activity of Luveltamab Tazevibulin (LT, STRO-002), a Novel Folate Receptor-α (FR-α)-Targeting Antibody Drug Conjugate (ADC) in Relapsed/Refractory CBF2AT3::GLIS2 AML

Oral Chemotherapy Adherence in Pediatric Acute Lymphoblastic Leukemia (ALL): A Report from the Dana-Farber Cancer Institute (DFCI) ALL Consortium Protocol 16-001

Performance of Next Generation Sequencing for Minimal Residual Disease Detection for Pediatric Patients with Acute Lymphoblastic Leukemia: Results from the Prospective Clinical Trial DFCI 16-001

Impact of Age, Body Surface Area, and Body Mass Index on Pegaspargase Toxicity and Pharmacokinetics: A Report from the DFCI ALL Consortium

Frequency and Prognostic Significance of Recurrent Gene Mutations in Pediatric B-ALL: Report from the DFCI ALL Consortium

Pegaspargase Re-Challenge after Grade 2 Hypersensitivity Reaction in Childhood Acute Lymphoblastic Leukemia: Results from DFCI 16-001

Genetic Ancestry and Skeletal Toxicities Among Childhood Acute Lymphoblastic Leukemia Patients in the DFCI 05-001 Cohort

Age and ABO Blood Group Are Significant Predictors of Thrombosis in Children with Acute Lymphoblastic Leukemia (ALL): Results from Dana-Farber Cancer Institute (DFCI) ALL Consortium Trial 05-001

Dietary Antioxidant Micronutrient Intake and Toxicity during Remission Induction in Children with Acute Lymphoblastic Leukemia (ALL): Results from Dana-Farber Cancer Institute (DFCI) ALL Consortium Trial 05-001

Randomized Study of Pegasparagase (SS-PEG) and Calaspargase Pegol (SC-PEG) in Pediatric Patients with Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma: Results of DFCI ALL Consortium Protocol 11-001

Kinase-Activating Fusions in Pediatric High-Risk B-Lineage Acute Lymphoblastic Leukemia (ALL): a Report from the Dana-Farber Cancer Institute (DFCI) ALL Consortium

Excellent Outcome of Children with Down Syndrome (DS) and Acute Lymphoblastic Leukemia (ALL) Treated on Dana-Farber Cancer Institute (DFCI) ALL Consortium Protocols 00-001 and 05-001

Higher Incidence of Treatment-Related Toxicities in Non-Hispanic Patients Undergoing Therapy for Newly Diagnosed Pediatric Acute Lymphoblastic Leukemia on Dana-Farber Cancer Institute ALL Consortium Protocol 05-001

Effectiveness of Antibacterial Prophylaxis during Induction Chemotherapy in Children with Acute Lymphoblastic Leukemia

Ikaros Gene Deletion Significantly Predicts Relapse in Pediatric B-ALL Patients with Low End-Induction Minimal Residual Disease

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only